Rinvoq is available as an extended-release oral tablet or as an oral solution. It is approved to treat:
Rheumatoid arthritis
Psoriatic arthritis
Atopic dermatitis (eczema)
Ulcerative colitis
Crohn's disease
Ankylosing spondylitis
Non-radiographic axial spondyloarthritis
Polyarticular juvenile idiopathic arthritis
Giant cell arteritis
Rinvoq is an oral drug classified as a Janus kinase (JAK) inhibitor. It is not a biologic. JAK inhibitors help regulate an overactive immune system and interfere with signals in the body that are thought to cause inflammation.
